These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Isoquercetin ameliorated hypoxia/reoxygenation-induced H9C2 cardiomyocyte apoptosis via a mitochondrial-dependent pathway.
    Author: Cao H, Xu H, Zhu G, Liu S.
    Journal: Biomed Pharmacother; 2017 Nov; 95():938-943. PubMed ID: 28915535.
    Abstract:
    Isoquercetin exerts multiple pharmacological effects against various diseases. The present research sought to further investigate the role of isoquercetin in hypoxia/reoxygenation (H/R)-treated cardiomyocytes and its potential mechanism involved. The H/R model in H9C2 cells was established to mimic myocardial I/R injury in vitro. Cell proliferation and apoptosis were tested using MTT assay and Annexin V FITC-PI staining assay, respectively. We found that isoquercetin protected H9C2 cells from H/R-induced injury as the evidences that isoquercetin administration attenuated the effects of H/R treatment on H9C2 cell viability, cell apoptosis and ROS generation after H/R treatment. More importantly, isoquercetin protects mitochondrial function and prevents cytochrome c release in H9C2 cells after I/R injury. In conclusion, these results revealed the potential cardiovascular protective effects of isoquercetin in the treatment of I/R-related myocardial injury.
    [Abstract] [Full Text] [Related] [New Search]